These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26634274)

  • 1. Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.
    Rajabalaya R; David SR; Chellian J; Xin Yun G; Chakravarthi S
    Drug Deliv; 2016 Jun; 23(5):1578-87. PubMed ID: 26634274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder.
    Rajabalaya R; Leen G; Chellian J; Chakravarthi S; David SR
    Pharmaceutics; 2016 Aug; 8(3):. PubMed ID: 27589789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.
    Aboelwafa AA; El-Setouhy DA; Elmeshad AN
    AAPS PharmSciTech; 2010 Dec; 11(4):1591-602. PubMed ID: 21063815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
    Yasam VR; Jakki SL; Natarajan J; Venkatachalam S; Kuppusamy G; Sood S; Jain K
    Drug Deliv; 2016; 23(2):619-30. PubMed ID: 25005581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and evaluation of proniosomes containing lornoxicam.
    Madan JR; Ghuge NP; Dua K
    Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits.
    Soliman SM; Abdelmalak NS; El-Gazayerly ON; Abdelaziz N
    Drug Deliv; 2016 Jun; 23(5):1608-22. PubMed ID: 26758033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.
    Sheng Y; Zhang S; Ling J; Hu C; Zhang Z; Lv H
    Pharm Dev Technol; 2022 Apr; 27(4):459-468. PubMed ID: 35575444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of transdermal therapy for overactive bladder.
    Sand PK
    Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
    Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
    Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
    Abdelbary GA; Aburahma MH
    J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
    Wen MM; Farid RM; Kassem AA
    J Liposome Res; 2014 Dec; 24(4):280-9. PubMed ID: 24779560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of methotrexate loaded niosomes by Box-Behnken design: an understanding of solvent effect and formulation variability.
    Zidan AS; Mokhtar Ibrahim M; Megrab NAE
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1450-1459. PubMed ID: 28420295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.